Molecularly targeted therapies for acute myeloid leukemia
- PMID: 26637775
- DOI: 10.1182/asheducation-2015.1.579
Molecularly targeted therapies for acute myeloid leukemia
Abstract
The past 15 years have seen major leaps in our understanding of the molecular genetic mutations that act as drivers of acute myeloid leukemia (AML). Clinical trials of agents against specific mutant proteins, such as FLT3-internal tandem duplications (ITDs) and isocitrate dehydrogenase mutations (IDHs) are ongoing. This review discusses agents in clinical trials that target specific gene mutations and/or epigenetic targets.
© 2015 by The American Society of Hematology. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
